Publications

A list of Prof. Dr. Adelheid Cerwenka's publications can be also found on PubMed.

Most important publications

• von Kries, A., Garcés-Lázaro, I., Balzasch, B. M., Sticht, C., Shaltiel, I. A., Boonekamp, K. E., Sams, A., Triassi, A., Hofman, T., Burgermeister, E., Betge, J., Ebert, M., Boutros, M., Helming, L., Stojanovic, A., & Cerwenka, A. (2025). Colorectal cancer organoids drive hypoxia, TGF-β, and patient-specific diversification of NK cell activation programs. Journal for immunotherapy of cancer, 13(12), e012988. https://doi.org/10.1136/jitc-2025-012988

• Hofman T, Ng SW, Garcés-Lázaro I, Heigwer F, Boutros M, Cerwenka A. IFNγ mediates the resistance of tumor cells to distinct NK cell subsets. J Immunother Cancer. 2024 Jul 1;12(7):e009410. doi: 10.1136/jitc-2024-009410. PMID: 38955423; PMCID: PMC11218003. Project design and supervision: Report on a strategy to unleash the reactivity of all NK subsets against cancer by combining anti-NKG2A, and anti-KIR therapeutic mAbs.

• Papaioannou S, See JX, Jeong M, De La Torre C, Ast V, Reiners-Koch PS, Sati A, Mogler C, Platten M, Cerwenka A*, Stojanovic A*. Liver sinusoidal endothelial cells orchestrate NK cell recruitment and activation in acute inflammatory liver injury. Cell Rep. 2023 Aug 29;42(8):112836. doi: 10.1016/j.celrep.2023.112836. Epub 2023 Jul 19. PMID: 37471222.

• Correia MP, Stojanovic A, Wels WS, Cerwenka A. Innate-like NKp30+CD8+ T cells armed with TCR/CAR target tumor heterogeneity. Oncoimmunology. 2021 Oct 19;10(1):1973783. doi: 10.1080/2162402X.2021.1973783. PMID: 35036073; PMCID: PMC8758178.

• Stojanovic, A., & Cerwenka, A. (2021). An intimate encounter: DC3s empower anti-tumor CTLs. Cancer cell, 39(9), 1181–1183. doi:10.1016/j.ccell.2021.08.010

• Ferreira C, Barros L, Baptista M, Blankenhaus B, Barros A, Figueiredo-Campos P, Konjar Š, Lainé A, Kamenjarin N, Stojanovic A, Cerwenka A, Probst HC, Marie JC, Veldhoen M. Type 1 Treg cells promote the generation of CD8+ tissue-resident memory T cells. Nat Immunol. 2020 Jul;21(7):766-776. doi: 10.1038/s41590-020-0674-9. Epub 2020 May 18.

• Ni J, Wang X, Stojanovic A, Zhang Q, Wincher M, Bühler L, Arnold A, Correia MP, Winkler M, Koch PS, Sexl V, Höfer T, Cerwenka A. Single-Cell RNA Sequencing of Tumor-Infiltrating NK Cells Reveals that Inhibition of Transcription Factor HIF-1α Unleashes NK Cell Activity. Immunity. 2020 Jun 16;52(6):1075-1087.e8. doi: 10.1016/j.immuni.2020.05.001. Epub 2020 May 22.PMID: 32445619

• Stojanovic A, Cerwenka A. Checkpoint inhibition: NK cells enter the scene. Nat Immunol. 2018 Jul;19(7):650-652. doi: 10.1038/s41590-018-0142-y. No abstract available.

• Correia MP, Stojanovic A, Bauer K, Juraeva D, Tykocinski LO, Lorenz HM, Brors B, Cerwenka A. Distinct human circulating NKp30+FcεRIγ+CD8+ T cell population exhibiting high natural killer-like antitumor potential. Proc Natl Acad Sci U S A. 2018 Jun 26;115(26):E5980-E5989. doi: 10.1073/pnas.1720564115. Epub 2018 Jun 12

• Pahl JHW, Koch J, Götz JJ, Arnold A, Reusch U, Gantke T, Rajkovic E, Treder MS, Cerwenka A. CD16A activation of NK cells promotes NK cell proliferation and memory-like cytotoxicity against cancer cells. Cancer Immunol Res. 2018 May;6(5):517-527. doi: 10.1158/2326-6066.CIR-17-0550. Epub 2018 Mar 7.

• Cerwenka A, Lanier LL. Natural killers join the fight against cancer. Science. 2018 Mar 30;359(6383):1460-1461. doi: 10.1126/science.aat2184. No abstract available.

• Pollmann J, Götz JJ, Rupp D, Strauss O, Granzin M, Grünvogel O, Mutz P, Kramer C, Lasitschka F, Lohmann V, Björkström NK, Thimme R, Bartenschlager R, Cerwenka A. Hepatitis C virus-induced natural killer cell proliferation involves monocyte-derived cells and the OX40/OX40L axis. J Hepatol. 2018 Mar;68(3):421-430. doi: 10.1016/j.jhep.2017.10.021. Epub 2017 Nov 1.

• Cerwenka A, Lanier LL. NK cell memory in viral infection, inflammation and cancer. Nature Immunology Reviews 2016 Feb;16(2):112-23. doi: 10.1038/nri.2015.9.

• Stojanovic A, Fiegler N, Brunner-Weinzierl M and Cerwenka A. CTLA-4 is expressed by activated mouse NK cells and inhibits NK cell IFN-g production in response to mature dendritic cells. J Immunol. 2014 May 1;192(9):4184-91.

• Fiegler N, et al.  Cerwenka A. Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells. Blood  2013, 122(5):684-693.

• Cerwenka A, Bakker ABH,  McClanahan T, Wagner J, Wu J, Phillips JH and Lanier LL. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity. 2000, 12: 721-727.